Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00957671 · ClinicalTrials.gov registry record · Phase 4
Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
A Phase 4 study, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00957671 is a Phase 4 study that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 15 participants.
The verdict
NCT00957671, a Phase 4 study, has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
Fifteen to twenty percent of adults who suffer a traumatic brain injury (TBI) that requires hospitalization and rehabilitation have been found to have growth hormone (GH) deficiency by GH stimulation testing. Moreover, abnormalities have also been established for the cortisol and thyroid axis. The hypothesis of this proposal is that hormone replacement in TBI patients with documented abnormalities in the GH, thyroid, or cortisol axis will improve muscle function, body composition, aerobic capacity (GH) and tests of neuropsychologic function (GH, thyroid, cortisol).
Interventions
- DRUG Recombinant human growth hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2003-11 |
| Est. Completion | 2015-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00957671
The ClinicalTrials.gov registry entry for NCT00957671 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant human growth hormone is the first listed.
NCT00957671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00957671 about?
NCT00957671 is a clinical study titled "Anterior Pituitary Hormone Replacement in Traumatic Brain Injury". Fifteen to twenty percent of adults who suffer a traumatic brain injury (TBI) that requires hospitalization and rehabilitation have been found to have growth hormone (GH) deficiency by GH stimulation testing. Moreover, abnormalities have also been established for the cortisol and thyroid axis. The h...
What is the current status of trial NCT00957671?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2003-11. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00957671?
The interventions under investigation include: Recombinant human growth hormone (DRUG).
Who is sponsoring clinical trial NCT00957671?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.